I-Darunavir CAS 206361-99-1 Anti-HIV Purity ≥99.0% API High Purity HIV Protease Inhibitor
Umkhiqizi SupplyImikhiqizo Ehlobene ne-Darunavir:
I-Darunavir CAS 206361-99-1
I-Darunavir Ethanolate CAS 635728-49-3
(2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98737-29-2
(2R,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98760-08-8
(3S)-3-(tert-Butoxycarbonyl)amino-1-Chloro-4-Phenyl-2-Butanone CAS 102123-74-0
| Igama Lekhemikhali | I-Darunavir |
| Omqondofana | I-TMC114;I-UIC-94017 |
| Inombolo ye-CAS | 206361-99-1 |
| Inombolo yeCAT | I-RF-API68 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
| I-Molecular Formula | I-C27H37N3O7S |
| Isisindo samangqamuzana | 547.66 |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Ukubukeka | I-Crystalline Powder Emhlophe noma Engamhlophe |
| Ukuhlonza | I-MS/HNMR HPLC |
| Ukuncibilika | I-Soluble ku-DMSO, Incibilika Kancane Emanzini |
| I-Melting Point | 74.0 ~ 76.0℃ |
| Ukuhlonza | 1H NMR |
| Ukuhlanzeka / Indlela Yokuhlaziya | ≥99.0% (HPLC) |
| Izinto Ezihlobene | |
| Ukungcola Okukodwa Okukhulu | ≤0.30% |
| Ukungcola Okuphelele | ≤1.0% |
| Izincibilikisi Ezisele | I-Ethanol ≤0.30% |
| Ukulahlekelwa Ekumisweni | ≤0.50% |
| Izinsalela ekushiseni | ≤0.10% |
| Izinsimbi Ezisindayo | ≤20ppm |
| I-Arsenic | ≤1.5ppm |
| Izinga Lokuhlola | I-Enterprise Standard |
| Ukusetshenziswa | I-Darunavir (CAS 206361-99-1) i-HIV-1 Protease Inhibitor Anti-HIV |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, I-Cardboard Drum, 25kg/Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni, umswakama kanye nezinambuzane.
I-Darunavir (igama lomkhiqizo i-Prezista, phambilini eyayaziwa ngokuthi i-TMC114) umuthi we-protease inhibitor osetshenziselwa ukwelapha ukutheleleka nge-HIV.I-Darunavir iyindlela yokwelapha enconyiwe ye-OARAC yabantu abadala nentsha enolwazi ngokwelashwa.I-Darunavir uhlobo olusha lwe-non-peptide anti-retroviral protease inhibitors ekwelashweni kwe-AIDS.Yasungulwa okokuqala yigatsha lase-Island le-Johnson pharmaceutical, i-Tibotec.Isezingeni eliphezulu kakhulu le-bioavailability kuma-6 protease inhibitors (saquinavir, ritonavirvir, indinavir, naphthalene nelfinavir, amprenavir kanye ne-ABT378/r).Isebenza ngokuvimbela ukwakheka kwezinhlayiya zegciwane ezintsha nezivuthiwe ebusweni bamaseli aphethwe yigciwane futhi ivimbele i-protease yegciwane.Uma umkhiqizo usetshenziswa isikhathi eside, ngokuvamile unganciphisa i-HIV virus vector egazini, ukhuphule isibalo samaseli e-CD4, unciphise amathuba okutheleleka nge-HIV, uthuthukise izinga lempilo futhi andise impilo.Ilungele abantu abadala abanegciwane lesandulela ngculazi kodwa abangenawo amandla okusebenzisa imishanguzo ekhona.Umuthi kufanele uhlanganiswe nokusetshenziswa kwemithamo ephansi ye-ritonavir noma amanye ama-antiretroviral agents, ukuze kuthuthukiswe ukusebenza kahle kwawo.Umsebenzi we-antiviral in vitro ungahlolwa ngokuba ngokumelene nama-lymphocyte anesifo esinamandla futhi esingamahlalakhona kanye nama-lymphocyte egazini le-peripheral.
